Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Go back to Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 161.62 +3.33 (2.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.29 | 52 Week High | $58.46 | |||
| Open | $161.17 | 52 Week Low | $31.25 | |||
| Day High | $161.79 | P/E | N/A | |||
| Day Low | $159.32 | EPS | $-0.69 | |||
| Volume | 1,008,849 | |||||
